This is my second independent submission on material from the same supplier.
I would like to define my thresholds before I have a result, for obvious reasons.
I want a plan with explicit stopping rules, not just steps.
What does a sensible plan look like, and what are the decision points?
No. Nine per cent short of a 10 mg label is 9.1 mg, and the pharmacopoeial content tolerance for a finished peptide preparation is conventionally ±5 per cent — so nine per cent is close to twice the outside of it. Restate it as dose, because that is where it lands: every draw you take is 9 per cent light. A 2.4 mg intended dose is 2.18 mg, and across the life of one vial the cumulative shortfall is most of one further dose. Then separate the two things a shortfall can be. Analytical uncertainty on a content assay against a well-characterised reference standard runs a couple of per cent, so nine is outside it — this is a real difference, not a measurement argument. And it is not a purity problem. Net peptide content excludes water and counter-ion; a vial can be 99 per cent pure by area and still be 9 per cent under label, because purity is a ratio among the peaks and content is a mass in the glass. A supplier who answers a content question with a purity certificate has changed the subject. What a nine per cent gap does justify is a second vial from the same lot: one assay is a measurement, two is evidence about the lot.
Concretely, content assay and purity are orthogonal measurements answering orthogonal questions, and the confusion between them is one of the most expensive misreadings in this space.
Water content and counter-ion content are part of the gross mass but not part of the content assay result, which is why the two do not sum to label claim.
To be exact about it, peak area for a standard of known weight produces a response factor — area per unit mass — which is then applied to the sample peak to infer sample mass.
Quantitation against a standard requires that the standard be traceable to a national metrology institute, and certificates for research-grade standards claim that traceability.
The practical summary: if you are ordering from a new supplier, budget for content assay on the first lot.
Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.
Shop standardsMore usefully, if a supplier quotes a content figure without stating the purity of their reference standard, they have not told you the uncertainty in the number.
Comparing content results from different laboratories requires knowing whether they both used certified reference materials or whether one used an in-house standard of unknown provenance.
The purity of the reference standard is stated on its certificate, and your content figure is only as good as that purity certificate is.
Pharmacopoeial guidance on quantitative methods specifies validation steps for linearity, range, accuracy and precision that most research-grade work does not claim to meet.
Worth noting that the standard certificate carries its own uncertainty, usually on the order of two to three per cent, which the sample result inherits.
Ask for both the purity and the content, and do not accept purity alone.
edited 11 Feb 2026 by kwn_analytical — added the method parameters
The honest answer is that you cannot know for certain what you have without a content assay, and the purity number alone is not enough.
If a sample shows high purity but low content, the explanation is usually that the standard used for quantitation had a different purity than claimed.
If the standard and sample have different absorption coefficients at the detection wavelength, the response factors differ and the inference fails.
Where content data have been published from testing services on common peptides, the spread between services on identical material is typically a few per cent.
One qualification: a single result from a single vial is a point estimate, and repeating the assay on a second aliquot is worth doing if the first result is surprising.
If a supplier gives you content without the standard's purity, ask them to provide it.
Two measures of the same vial can agree on purity and disagree on content by a few per cent, which usually means the content assay used a different standard.
For peptides at 214 nanometres the response is roughly proportional to the number of peptide bonds, so truncation impurities have lower response factors and overestimate content.
The relative standard deviation on replicate quantitations of a homogeneous sample should be below two per cent when the method is under control.
The caveat is that content assay costs more than purity, so most people do not do it, which is exactly why it is valuable on the first lot from a new supplier.
If you only pay for one test, pay for quantified content. Purity is the number everyone quotes and content is the number that changes what you do.
Put another way, content assay requires a reference standard of known purity and traceability, which is why it costs more than purity testing does.
Running multiple independent aliquots of the same sample should give results that agree to within the method precision, which is usually one to three per cent.
The ICH Q3A and Q3B thresholds for reporting, identification and qualification of impurities are the framework the pharmaceutical industry works to, and they are worth reading even though nothing in the research-grade supply chain is obliged to meet them, because they tell you which numbers a competent analyst would consider worth reporting at all.
In practice: ask for the chromatogram, check the method section, check the lot number against the vial, and set your accept threshold before you see the result rather than after.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.